Cadila, India’s fourth largest healthcare Group and an innovation-led global healthcare provider and IDRI a Seattle-based non-profit research and product development organization has collaborated on the production and clinical development of IDRl ‘s visceral leishmaniasis (VL) vaccine candidate, designed to prevent the deadly parasitic disease.
0 comments:
Post a Comment